Markets open

PFE Pfizer

Healthcare · Close of 19 Nov 26

$27.54 -1.85%

⭐ Log in to follow stocks and set price alerts (free) Log in

21 Apr 2025SMA5019 Nov 2026
1 month-7.74%
3 months-1.89%
Year to date+10.60%
1 year+8.21%
52-week range$23.62 – $31.44
SMA50 / SMA200$28.83 / $27.02
RSI 1433
Avg daily move (ATR)2.8%
TrendMixed

📊 Latest results (3 Nov 26)

Pfizer Q3 2026: Revenue flat, EPS lower, but full-year guidance raised

  • Revenue: $16.6B, nearly unchanged from $16.65B a year earlier. Excluding Comirnaty and Paxlovid, revenue grew 7% operationally (excluding currency effects).
  • EPS: GAAP diluted EPS was $0.56, down 9% from $0.62. Adjusted diluted EPS was $0.87, flat year over year.
  • Drivers: Eliquis rose $513M (25%), Padcev $255M (55%), and the Vyndaqel family 12%. Paxlovid fell 63% and Comirnaty fell 29%.
  • Cash/dividends: In the first nine months, Pfizer paid $7.3B in dividends and invested $8.3B in internal R&D. No share repurchases have been made in 2026.
  • Company's outlook: 2026 revenue of $62.0–64.0B (previously $60.5–62.5B) and adjusted EPS of $2.95–3.05 (previously $2.80–3.00).

Note: These are the company's reported, unaudited numbers.

AI summary of the release the company filed with the SEC (company-reported, unaudited) · Read the original release (SEC)

Financials (from SEC filings)

📅 Next earnings: 2 Feb 2027 · date estimated from last year

Revenue (TTM)$63.6B
Net income (TTM)$4.0B
EPS (TTM)$0.70
P/E (price ÷ EPS)39.3
Market cap$157B
Net margin6.3%

What changed in the latest quarter (Q3 2026)

Pfizer (PFE) – Q3 2026 (quarter ended Sep 27, 2026)

  • Revenue: $16.6B, about 0.4% lower than a year earlier, so basically flat.
  • Margins: Gross margin rose to 75.7% from 74.9%. Net margin fell to 19.6% from 21.3%. Operating margin was not provided.
  • Profit: Net income was $3.2B, down 8.4%. EPS was $0.56 vs $0.62, down 9.7%.
  • Balance sheet: Cash was $1.8B, while long-term debt was $60.0B.

This is a reported quarter from the 10-Q, not a derived one. In short: sales held steady and the company kept more of each sales dollar after direct costs, but net profit shrank compared with last year.

QuarterRevenueNet incomeEPSNet margin
Q3 2026ended 27 Sept 2026 $16.6B-0.4% YoY $3.2B-8.4% YoY $0.56-9.7% YoY 19.6%
Q2 2026ended 28 Jun 2026 $15.0B+2.6% YoY −$248M-108.5% YoY $-0.04-107.8% YoY -1.6%
Q1 2026ended 29 Mar 2026 $14.5B+5.4% YoY $2.7B-9.4% YoY $0.47-9.6% YoY 18.6%
Q4 2025*ended 31 Dec 2025 $17.6B-1.2% YoY −$1.6B-501.7% YoY $-0.29-514.3% YoY -9.4%
Q3 2025ended 28 Sept 2025 $16.7B-5.9% YoY $3.5B-20.7% YoY $0.62-20.5% YoY 21.3%
Q2 2025ended 29 Jun 2025 $14.7B+10.3% YoY $2.9B+6997.6% YoY $0.51+5000.0% YoY 19.9%

YoY = vs the same quarter a year earlier · quarters follow the company's fiscal year * Q4 = full year minus the first three quarters (EPS approximate)

Balance sheet as of 2026-09-27: Cash $1.8B · Long-term debt $60.0B · Equity $89.0B

Numbers from SEC EDGAR (the company's 10-Q/10-K filings), updated daily · AI summary from the numbers only, not investment advice ·Open the 10-Q filed 2026-11-03

🏛 US Congress trades in this stock (12 months)

Reports can arrive up to 45 days after the trade and give amount ranges only. By the time you see this, the trade is old news: no inside information, not a trading signal.

FiledMemberAsset Type Amount (range) Traded
13 Aug 26PDFCarol Devine MillerWV01 · spousePFEPfizer, Inc. Common Stock Sell $15,001 - $50,000 10 Mar 25521 days later

See all trades

Today's AI analysis

Based on the close of 5 Nov 26

The picture now

Pfizer (PFE) closed at $29.88 on 2026-11-05, down 2.96% on the day. That puts it about 80% of the way up its 52-week range ($23.62 to $31.44), roughly 5% below the high. The trend is up: the price is about 4% above the SMA50 ($28.72), which is itself well above the SMA200 ($26.89). Returns are positive across the board: +6.71% over 1 month, +11.66% over 3 months, +20.0% year to date and +22.96% over 1 year.

Momentum and risk

RSI14 is 54.1, a neutral reading, neither hot (over 70) nor weak (under 30). So today's drop did not leave the stock overextended in either direction. ATR14 is 2.48% of price, about $0.74, which is the typical daily move. Today's decline was a little larger than that. Average 20-day volume is about 33.5 million shares, a useful baseline for judging whether future moves have strong participation.

Levels to watch

  • SMA50 (~$28.72): the first support area in an uptrend.
  • SMA200 (~$26.89): a deeper, longer-term level.
  • 52-week high ($31.44): the key resistance. 52-week low ($23.62): the far downside marker.

Main scenario: the uptrend holds, the price steadies near or above the SMA50, and it eventually retests the $31.44 high. Alternative scenario: a sustained close below the SMA50 would point to a deeper pullback toward the SMA200.

Confidence: moderate, since the trend is clear but today's drop shows short-term volatility.

Educational analysis, not investment advice.

For education only, not a recommendation to buy or sell. Investing involves risk.